EN
English
59
BEXSERO
Multicomponent Meningococcal B Vaccine
(recombinant, adsorbed)

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site
Registration successful
You now have access to the latest updates, events and resources.
Event Registration successful
You now have sucesfully register for the event and you can also access the latest updates, events and resources.
In case you would like to receive SMS-reminders for the event you have registered, please scroll down to provide your mobile number.
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Event registration completed - pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We'll send you and email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.
Account activated - pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy the public content on our website
Event Account activated - pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy the public content on our website
In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.
already registered
59
Thank you for visiting AREXVYhcp.ca. GSK offers, as a convenience, links to third-party websites that we believe may offer useful information to our visitors (“Linked Sites”). GSK makes no warranty regarding the availability of the Linked Sites, does not review or endorse the Linked Sites, and shall not be liable, directly or indirectly, for how the Linked Sites treat your personally identifiable information, the content of the Linked Sites, and the use that others make of the Linked Sites. Would you like to continue?
true
* The initial course can also be given as 3 injections with ≥1 month interval between the primary doses. A booster dose should be given in the 2nd year of life after an interval of ≥6 months from the last injection of the initial course.
† The need for, and timing of further doses has not yet been determined.
BEXSERO should be given by deep intramuscular injection, preferably in the anterolateral aspect of the thigh in infants or in the deltoid muscle region of the upper arm in older subjects. The vaccine must not be mixed with other vaccines or medicinal products in the same syringe.
When given concomitantly with other vaccines, BEXSERO should be administered at a different injection site. BEXSERO must not be mixed with other medicinal products or other vaccines in the same syringe.
Sufficient data are not available on the safety and effectiveness of using BEXSERO and other meningococcal group B vaccines interchangeably to complete the vaccination series. Therefore, it is recommended that subjects who receive a first dose of BEXSERO complete the vaccination course with BEXSERO.
Your patients can visit the consumer website BEXSERO.ca for a handy dose planner. They can also sign up for dose reminders via text or email.
For children, adolescents and adults aged 2 through 25 years, the second dose should be administered not less than one month after the first dose; a booster should be considered in individuals at continued risk of exposure to meningococcal disease, based on guideline recommendations.
BEXSERO can be given concomitantly with any of the following vaccine antigens (either as monovalent or as combination vaccines):
As higher percentages of subjects reported systemic reactions, including fever, change in eating habits, tenderness at the injection site and irritability, following BEXSERO given concomitantly with routine vaccines than after BEXSERO alone, separate vaccinations can be considered when possible. Prophylactic use of acetaminophen reduces the incidence and severity of fever without affecting the immunogenicity of either BEXSERO or most antigens of routine vaccines. The effect of antipyretics other than acetaminophen on the immune response has not been studied.
Concomitant administration of BEXSERO with vaccines other than those mentioned above has not been studied.
BEXSERO should be given by deep intramuscular injection, preferably in the anterolateral aspect of the thigh in infants or in the deltoid muscle region of the upper arm in older subjects.
When given concomitantly with other vaccines, BEXSERO should be administered at a different injection site. BEXSERO must not be mixed with other medicinal products or other vaccines in the same syringe.
This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit our consumer website BEXSERO.ca.
Unit for Hours:H
Unit for Minutes: M
Loading text: $loading
Filter redirection page URL: events.html
Login overlay needed?: true
Filter Tags:Medical indications|Products|Therapy Areas
Filter Tags values when filtered by all Tags:All Medical indications|All Products|All Therapy Areas
OutofBox filter category name:Format
Filter Reset all button text:Reset All
Filter Apply button text:Apply
Events registration success message: Registration successfull
Events registration failure message: Registration failure
Events un-registration success message: Un-Registration successfull
Events un-registration failure message: Un-Registration failure
Reset all default value: false
Show More Naivagation Values: 10|15|20
Previous Text label: Previous
Next Text label: Next
Show Text label: Show
Seats left Text: spaces left
No Seats left Text: No spaces left
Text Area Blank copy in Email Template:Not Provided
Trademarks are owned by or licensed to the GSK group of companies.
© 2025 GSK group of companies or its licensor.
Please note: This site is intended for Canadian healthcare professionals only and is not intended as a means for reporting an adverse event (side effect) or complaint for any GlaxoSmithKline product. To report an adverse event or product complaint, please call 1-800-387-7374.
We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website, features and remember your preferences; advertising cookies help us share relevant content. Cookie Policy
Necessary for the website to function appropriately, such as store session data during a website visit, to manage cookie and tag preferences, and to protect the security of the website. In addition some cookies are set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Enable the website to provide enhanced functionality and personalization, such as by helping us to measure how many visitors come to our websites, what sites our website visitors come from, and how often certain pages on our website are viewed. These cookies may be set by us or by third party providers, like our analytics service providers, whose services we have added to our pages. Please note that performance cookies include functional cookies. For more information on functional cookies, please refer to the Cookie Policy.
Allow us to target and re-target you with the relevant advertising. We and our advertising partners use information collected through these technologies to infer your interests in order to serve you more relevant advertisements on other sites. If you don’t allow these cookies, you will receive advertising, but it may be less relevant to you.